Related Experiment Video
Updated: Jul 14, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab for advanced breast cancer
Tiffany A Traina1, Hope S Rugo, Maura Dickler
1Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. trainat@mskcc.org
Hematology/Oncology Clinics of North America
|May 22, 2007
Summary
Vascular endothelial growth factor (VEGF) drives tumor growth and spread. Anti-VEGF therapies like bevacizumab show promise for treating advanced breast cancer and other solid tumors.
Area of Science:
- Oncology
- Cancer Biology
- Medical Research
Background:
- Tumor angiogenesis is critical for solid tumor growth and metastasis.
- Elevated vascular endothelial growth factor (VEGF) levels correlate with poor prognosis in breast cancer patients.
- VEGF is a validated therapeutic target in breast cancer treatment.
Purpose of the Study:
- To review the clinical data on bevacizumab and other antiangiogenic agents for advanced breast cancer.
- To discuss the role of antiangiogenic therapies in managing metastatic breast cancer.
Main Methods:
- Review of clinical trial data and scientific literature on antiangiogenic agents.
- Focus on bevacizumab, an antibody targeting VEGF.
- Analysis of treatment outcomes in patients with advanced breast cancer.
Main Results:
- Bevacizumab has demonstrated significant clinical benefit in various solid tumors.
- Antiangiogenic agents, including bevacizumab, are being investigated for advanced breast cancer treatment.
- The data suggest a role for targeting VEGF in improving outcomes for breast cancer patients.
Conclusions:
- VEGF is a key mediator of tumor growth and metastasis, making it a viable therapeutic target.
- Bevacizumab and other antiangiogenic therapies represent an important strategy in the management of advanced breast cancer.
- Further research and clinical application of antiangiogenic agents are warranted for breast cancer treatment.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.